1 citations
,
March 2022 in “International Journal of Nutrology” Myo-inositol improves fertility and metabolic health in PCOS with fewer side effects than metformin.
June 2026 in “Mendeley Data” The "Hair Loss Therapeutics Drug Database" is a comprehensive resource detailing pharmacological agents for treating hair loss disorders such as androgenetic alopecia, alopecia areata, and pseudofolliculitis barbae. It includes information on each drug's chemical properties, pharmacological classification, mechanism of action, molecular target, pharmacokinetics, clinical efficacy, dosage regimens, safety profile, regulatory status, and therapeutic uses. The database is designed to aid food and drug companies in research, drug development, bioinformatics, QSAR modeling, clinical decision support, and education.
June 2026 in “Mendeley Data” The "Hair Loss Therapeutics Drug Database" is a comprehensive resource detailing pharmacological agents for treating hair loss disorders such as androgenetic alopecia, alopecia areata, and pseudofolliculitis barbae. It includes information on each drug's chemical properties, pharmacological classification, mechanism of action, molecular target, pharmacokinetics, clinical efficacy, dosage regimens, safety profile, regulatory status, and therapeutic uses. The database is designed to aid food and drug companies in research, drug development, bioinformatics, QSAR modeling, clinical decision support, and education.
June 2026 in “The Journal of Sexual Medicine” Finasteride may be linked to more psychiatric issues than dutasteride, but a definite cause isn't proven.
CD28 is a promising target for treating alopecia areata with belatacept.
CD28 is a promising target for treating alopecia areata with belatacept.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
March 2026 in “International Society of Hair Restoration Surgery” Minoxidil is a widely used treatment for androgenetic alopecia (AGA) in both men and women, available in topical forms of 2% and 5%. It is the only topical treatment for AGA that is FDA-approved and available over the counter, known for its excellent safety profile. Recent years have seen interest in low-dose oral minoxidil as a potential treatment option.
January 2026 in “Current Issues in Molecular Biology” FGF-7 helps hair grow by activating hair follicles and is a promising target for hair loss treatments.
January 2026 in “International Society of Hair Restoration Surgery” Tattoo machine-assisted drug delivery may improve hair growth in androgenetic alopecia.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” PRP shows promise for improving hair growth in early to moderate hair loss but needs standardized methods for consistent results.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
December 2025 in “Journal of Holistic Integrative Pharmacy” Pleuropterus multiflorus shows promise as a safe and effective treatment for androgenetic alopecia.
November 2025 in “Dermatology Reports” Microinfusion using tattoo devices effectively treats hair loss and skin conditions with minimal side effects.
November 2025 in “PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS” Taurine may help reduce hair loss by improving hair growth cycles.
August 2025 in “International Journal of Molecular Sciences” Topical minoxidil 5% is the most effective over-the-counter treatment for male hair loss.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ashwagandha may help with skin and hair issues, but more research is needed.
July 2025 in “Revista Eletrônica Acervo Científico” Hydroxychloroquine is most effective for scarring alopecias, especially when combined with other treatments.
June 2025 in “Medical alphabet” Fractional lasers, combined with topical therapy, are a promising and safe treatment for hair loss.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
May 2025 in “Medical Science Monitor” Concentrated growth factor shows promise for treating hair loss but needs more research.
Bempikibart may help regrow hair in people with alopecia areata.
March 2025 in “JAAD reviews.” Bimatoprost effectively improves eyelashes in chemotherapy patients.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Clascoterone cream effectively reduces acne severity and is safe for patients 12 and older.
January 2025 in “Journal of Cosmetic Dermatology” Exosomes may help with hair growth and scar healing, but more research is needed.
December 2024 in “Journal of General-Procedural Dermatology & Venereology Indonesia” Coix seed extract helped resolve onycholysis in an elderly woman.
July 2024 in “Skin Appendage Disorders” Low dose oral minoxidil is safe for treating hair loss in men.
June 2024 in “Research Square (Research Square)” Finasteride overdose can cause acute pancreatitis.
May 2024 in “Aktualʹnì problemi sučasnoï medicini: Vìsnik Ukraïnsʹkoï medičnoï stomatologìčnoï akademì” Spironolactone and clascoterone are promising acne treatments with fewer side effects.